FTSE MIB
33.898,66 +269,45 (+0,80%) Dow Jones
38.821,38 +145,70 (+0,38%) Nasdaq
16.259,45 +103,12 (+0,64%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,81 +0,70 (+0,90%) Bitcoin EUR
59.370,52 +126,98 (+0,21%)
Galecto, Inc. (GLTO)
| Chiusura precedente | 0,7001 |
| Aperto | 0,7283 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,6996 - 0,7283 |
| Intervallo di 52 settimane | 0,5000 - 3,7000 |
| Volume | |
| Media Volume | 210.990 |
| Capitalizzazione | 19,44M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,1300 |
| Prossima data utili | 29 lug 2024 - 02 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 6,00 |
GlobeNewswireGalecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, Galecto
- GlobeNewswire
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences. Management will also be available for one-on-one meetings. H.C. Wainwright 25th Annual Global Investment ConferenceDate
- GlobeNewswire
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis (IPF). The GALACTIC-1 trial did n
